» Articles » PMID: 38451301

Obesity and Tobacco Smoking Are Independently Associated with Poor Patient-reported Outcomes in SLE: a Cross-sectional Study

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 2024 Mar 7
PMID 38451301
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated associations of obesity and tobacco smoking with health-related quality of life (HRQoL), pain, fatigue, and functional impairment in systemic lupus erythematosus (SLE). Furthermore, we explored whether there was an effect modification between these two factors. We included adult SLE patients from the Linköping University Hospital (n = 325) in the present cross-sectional analysis. We further included population-based controls and performed cardinality matching to balance age and sex distributions with cases (n = 224). HRQoL was assessed with the EQ-5D index score; pain, fatigue, and overall SLE-related health state with visual analogue scales (VAS; 0 [best] to 100 [worst]); and functional impairment with the HAQ-DI. Unacceptable outcomes were defined as VAS scores corresponding to the 90th percentile derived from the matched controls. SLE patients reported worse scores than controls in all measures, and approximately 30% experienced unacceptable outcomes. When compared with normal-weight, obese SLE patients reported lower HRQoL, and greater functional impairment and risk of unacceptable pain (OR: 3.2; 95% CI 1.6-6.7) and fatigue (OR: 2.1; 95% CI 1.0-4.3). Similarly, the current smokers reported higher levels of functional impairment and a greater risk of unacceptable pain (OR: 3.8; 95% CI 1.8-8.2) and fatigue (OR: 2.8; 95% CI 1.3-5.9) than never smokers. The associations were independent of age, sex, disease duration, disease activity, and organ damage. There was no evidence of a synergistic effect between increased BMI and smoking on any outcome. In summary, obesity and smoking are risk factors for unacceptable patient-reported outcomes in SLE, regardless of clinical activity.

Citing Articles

Late-onset Systemic Lupus Erythematosus.

Mruthyunjaya P, Ahmed S, Botabekova A, Baimukhamedov C, Zimba O Rheumatol Int. 2025; 45(1):29.

PMID: 39812833 DOI: 10.1007/s00296-024-05784-1.


Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals.

Andraos R, Ahmad A, Wirestam L, Dahle C, Frodlund M, Ronnelid J Front Med (Lausanne). 2024; 11:1455673.

PMID: 39228805 PMC: 11368755. DOI: 10.3389/fmed.2024.1455673.


Impact of body mass index on mortality outcomes in intensive care patients with Staphylococcus aureus sepsis: A retrospective analysis.

Xu H, Liu Y, Niu H, Wang H, Zhan F PLoS One. 2024; 19(8):e0308471.

PMID: 39106284 PMC: 11302852. DOI: 10.1371/journal.pone.0308471.

References
1.
Arevalo-Bermudez M, Paradela S, Balboa-Barreiro V, Fonseca E . Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain. Lupus. 2020; 29(9):1021-1030. DOI: 10.1177/0961203320930094. View

2.
Tektonidou M, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis P, Protogerou A . Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. Autoimmun Rev. 2017; 16(3):308-312. DOI: 10.1016/j.autrev.2017.01.009. View

3.
Golder V, Ooi J, Antony A, Ko T, Morton S, Kandane-Rathnayake R . Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2017; 27(3):501-506. DOI: 10.1177/0961203317722412. View

4.
Vordenbaumen S, Kleefisch M, Sokolowski A, Dusing C, Richter J, Brinks R . Beneficial effects associated to a healthy lifestyle in systemic lupus erythematosus: A cross-sectional study. Lupus. 2023; 32(7):855-863. DOI: 10.1177/09612033231175289. View

5.
Brun M, Goll G, Jorgensen K, Sexton J, Gehin J, Sandanger O . Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. J Intern Med. 2022; 292(3):477-491. PMC: 9545769. DOI: 10.1111/joim.13495. View